IFNs, ISGylation and cancer: Cui prodest?

Cytokine and Growth Factor Reviews

Volumn 23, Issue 6, 2012, Pages 307-314

  Sgorbissa, Andrea ^a   Brancolini, Claudio ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Cancer; Interferon; ISG15; ISGylation; Microarray; USP18

Indexed keywords

ATM PROTEIN; BETA INTERFERON; INTERFERON; INTERFERON REGULATORY FACTOR 7; INTERFERON STIMULATED GENE PROTEIN; INTERFERON STIMULATED GENE PROTEIN 15; JANUS KINASE 1; MESSENGER RNA; NUCLEIC ACID BINDING PROTEIN; PEPTIDASE; PROTEIN UBE1L; PROTEIN UBE2L6; PROTEIN USP18; STAT1 PROTEIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CYTOKINE RELEASE; DRUG RESISTANCE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; NEOPLASM; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN ISGYLATION; PROTEIN MODIFICATION; PROTEIN PROCESSING; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; HUMANS; INTERFERONS; NEOPLASMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; UBIQUITINS;

EID: 84869879114     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2012.07.003     Document Type: Short Survey

References (114)

1. Trinchieri G. Type I interferon: friend or foe?. The Journal of Experimental Medicine 2010, 207(September (10)):2053-2063.
2. Borden E.C., Sen G.C., Uze G., Silverman R.H., Ransohoff R.M., Foster G.R., et al. Interferons at age 50: past, current and future impact on biomedicine. Nature Reviews Drug Discovery 2007, 6(December (12)):975-990.
3. Pestka S. The interferons: 50 years after their discovery, there is much more to learn. The Journal of Biological Chemistry 2007, 282(July (28)):20047-20051.
4. Platanias L.C. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nature Reviews Immunology 2005, 5(May (5)):375-386.
5. Savitsky D., Tamura T., Yanai H., Taniguchi T. Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunology, Immunotherapy 2010, 59(April (4)):489-510.
6. Reich N., Evans B., Levy D., Fahey D., Knight E., Darnell J.E. Interferon-induced transcription of a gene encoding a 15-kDa protein depends on an upstream enhancer element. Proceedings of the National Academy of Sciences U S A 1987, 84(September (18)):6394-6398.
7. Zhang D., Zhang D.E. Interferon-stimulated gene 15 and the protein ISGylation system. The Journal of Interferon and Cytokine Research 2011, 31(January (1)):119-130.
8. Knight E., Fahey D., Cordova B., Hillman M., Kutny R., Reich N., et al. A 15-kDa interferon-induced protein is derived by COOH-terminal processing of a 17-kDa precursor. The Journal of Biological Chemistry 1988, 263(April (10)):4520-4522.
9. Chang Y.G., Yan X.Z., Xie Y.Y., Gao X.C., Song A.X., Zhang D.E., et al. Different roles for two ubiquitin-like domains of ISG15 in protein modification. The Journal of Biological Chemistry 2008, 283(May (19)):13370-13377.
10. Meraro D., Gleit-Kielmanowicz M., Hauser H., Levi B.Z. IFN-stimulated gene 15 is synergistically activated through interactions between the myelocyte/lymphocyte-specific transcription factors, PU.1, IFN regulatory factor-8/IFN consensus sequence binding protein, and IFN regulatory factor-4: characterization of a new subtype of IFN-stimulated response element. The Journal of Immunology 2002, 168(June (12)):6224-6231.
11. Dieterich C., Relman D.A. Modulation of the host interferon response and ISGylation pathway by B. pertussis filamentous hemagglutinin. PLoS ONE 2011, 6(11):e27535.
12. Mossman K.L., Macgregor P.F., Rozmus J.J., Goryachev A.B., Edwards A.M., Smiley J.R. Herpes simplex virus triggers and then disarms a host antiviral response. Journal of Virology 2001, 75(January (2)):750-758.
13. Nicholl M.J., Robinson L.H., Preston C.M. Activation of cellular interferon-responsive genes after infection of human cells with herpes simplex virus type 1. Journal of General Virology 2000, 81(September (Pt 9)):2215-2218.
14. Hummer B.T., Li X.L., Hassel B.A. Role for p53 in gene induction by double-stranded RNA. Journal of Virology 2001, 75(August (16)):7774-7777.
15. Novakova Z., Hubackova S., Kosar M., Janderova-Rossmeislova L., Dobrovolna J., Vasicova P., et al. Cytokine expression and signaling in drug-induced cellular senescence. Oncogene 2010, 29(January (2)):273-284.
16. Wood L.M., Sankar S., Reed R.E., Haas A.L., Liu L.F., McKinnon P., et al. A novel role for ATM in regulating proteasome-mediated protein degradation through suppression of the ISG15 conjugation pathway. PLoS ONE 2011, 6(1):e16422.
17. Lou Z., Wei J., Riethman H., Baur J.A., Voglauer R., Shay J.W., et al. Telomere length regulates ISG15 expression in human cells. Aging (Albany NY) 2009, 1(July (7)):608-621.
18. Yuan W., Krug R.M. Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO Journal 2001, 20(February (3)):362-371.
19. Dastur A., Beaudenon S., Kelley M., Krug R.M., Huibregtse J.M. Herc5, an interferon-induced HECT E3 enzyme, is required for conjugation of ISG15 in human cells. The Journal of Biological Chemistry 2006, 281(February (7)):4334-4338.
20. Kim K.I., Yan M., Malakhova O., Luo J.K., Shen M.F., Zou W., et al. Ube1L and protein ISGylation are not essential for alpha/beta interferon signaling. Molecular and Cell Biology 2006, 26(January (2)):472-479.
21. Kim K.I., Giannakopoulos N.V., Virgin H.W., Zhang D.E. Interferon-inducible ubiquitin E2, Ubc8, is a conjugating enzyme for protein ISGylation. Molecular and Cell Biology 2004, 24(November (21)):9592-9600.
22. Zhao C., Beaudenon S.L., Kelley M.L., Waddell M.B., Yuan W., Schulman B.A., et al. The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-alpha/beta-induced ubiquitin-like protein. Proceedings of the National Academy of Sciences U S A 2004, 101(May (20)):7578-7582.
23. Lipkowitz S., Weissman A.M. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nature Reviews Cancer 2011, 11(Sep (9)):629-643.
24. Zou W., Zhang D.E. The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. The Journal of Biological Chemistry 2006, 281(February (7)):3989-3994.
25. Durfee L.A., Lyon N., Seo K., Huibregtse J.M. The ISG15 conjugation system broadly targets newly synthesized proteins: implications for the antiviral function of ISG15. Molecular Cell 2010, 38(June (5)):722-732.
26. Malakhov M.P., Malakhova O.A., Kim K.I., Ritchie K.J., Zhang D.E. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. The Journal of Biological Chemistry 2002, 277(March (12)):9976-9981.
27. Malakhova O.A., Kim K.I., Luo J.K., Zou W., Kumar K.G., Fuchs S.Y., et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO Journal 2006, 25(June (11)):2358-2367.
28. Ritchie K.J., Malakhov M.P., Hetherington C.J., Zhou L., Little M.T., Malakhova O.A., et al. Dysregulation of protein modification by ISG15 results in brain cell injury. Genes and Development 2002, 16(September (17)):2207-2212.
29. Burkart C., Fan J.B., Zhang D.E. Two independent mechanisms promote expression of an N-terminal truncated USP18 isoform with higher DeISGylation activity in the nucleus. The Journal of Biological Chemistry 2012, 287(February (7)):4883-4893.
30. Potu H., Sgorbissa A., Brancolini C. Identification of USP18 as an important regulator of the susceptibility to IFN-alpha and drug-induced apoptosis. Cancer Research 2010, 70(January (2)):655-665.
31. Kang D., Jiang H., Wu Q., Pestka S., Fisher P.B. Cloning and characterization of human ubiquitin-processing protease-43 from terminally differentiated human melanoma cells using a rapid subtraction hybridization protocol RaSH. Gene 2001, 267(April (2)):233-242.
32. Malakhova O., Malakhov M., Hetherington C., Zhang D.E. Lipopolysaccharide activates the expression of ISG15-specific protease UBP43 via interferon regulatory factor 3. The Journal of Biological Chemistry 2002, 277(April (17)):14703-14711.
33. Guo Y., Dolinko A.V., Chinyengetere F., Stanton B., Bomberger J.M., Demidenko E., et al. Blockade of the ubiquitin protease UBP43 destabilizes transcription factor PML/RARalpha and inhibits the growth of acute promyelocytic leukemia. Cancer Research 2010, 70(December (23)):9875-9885.
34. Catic A., Fiebiger E., Korbel G.A., Blom D., Galardy P.J., Ploegh H.L. Screen for ISG15-crossreactive deubiquitinases. PLoS ONE 2007, 2(7):e679.
35. Zheng H., Qian J., Baker D.P., Fuchs S.Y. Tyrosine phosphorylation of protein kinase D2 mediates ligand-inducible elimination of the Type 1 interferon receptor. The Journal of Biological Chemistry 2011, 286(October (41)):35733-35741.
36. Francois-Newton V., Magno de Freitas Almeida G., Payelle-Brogard B., Monneron D., Pichard-Garcia L., Piehler J., et al. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response. PLoS ONE 2011, 6(7):e22200.
37. Sarasin-Filipowicz M., Wang X., Yan M., Duong F.H., Poli V., Hilton D.J., et al. Alpha interferon induces long-lasting refractoriness of JAK-STAT signaling in the mouse liver through induction of USP18/UBP43. Molecular and Cell Biology 2009, 29(September (17)):4841-4851.
38. Malakhova O.A., Yan M., Malakhov M.P., Yuan Y., Ritchie K.J., Kim K.I., et al. Protein ISGylation modulates the JAK-STAT signaling pathway. Genes and Development 2003, 17(February (4)):455-460.
39. Kim K.I., Malakhova O.A., Hoebe K., Yan M., Beutler B., Zhang D.E. Enhanced antibacterial potential in UBP43-deficient mice against Salmonella typhimurium infection by up-regulating type I IFN signaling. The Journal of Immunology 2005, 175(July (2)):847-854.
40. Ritchie K.J., Hahn C.S., Kim K.I., Yan M., Rosario D., Li L., et al. Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nature Medicine 2004, 10(December (12)):1374-1378.
41. Knobeloch K.P., Utermohlen O., Kisser A., Prinz M., Horak I. Reexamination of the role of ubiquitin-like modifier ISG15 in the phenotype of UBP43-deficient mice. Molecular and Cell Biology 2005, 25(December (24)):11030-11034.
42. Duex J.E., Sorkin A. RNA interference screen identifies Usp18 as a regulator of epidermal growth factor receptor synthesis. Molecular Biology of the Cell 2009, 20(March (6)):1833-1844.
43. Duex J.E., Comeau L., Sorkin A., Purow B., Kefas B. Usp18 regulates epidermal growth factor (EGF) receptor expression and cancer cell survival via microRNA-7. The Journal of Biological Chemistry 2011, 286(July (28)):25377-25386.
44. Hsiang T.Y., Zhao C., Krug R.M. Interferon-induced ISG15 conjugation inhibits influenza A virus gene expression and replication in human cells. Journal of Virology 2009, 83(June (12)):5971-5977.
45. Lenschow D.J., Lai C., Frias-Staheli N., Giannakopoulos N.V., Lutz A., Wolff T., et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proceedings of the National Academy of Sciences U S A 2007, 104(January (4)):1371-1376.
46. Okumura A., Lu G., Pitha-Rowe I., Pitha P.M. Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proceedings of the National Academy of Sciences U S A 2006, 103(January (5)):1440-1445.
47. Okumura A., Pitha P.M., Harty R.N. ISG15 inhibits Ebola VP40 VLP budding in an l-domain-dependent manner by blocking Nedd4 ligase activity. Proceedings of the National Academy of Sciences U S A 2008, 105(March 10):3974-3979.
48. Osiak A., Utermohlen O., Niendorf S., Horak I., Knobeloch K.P. ISG15, an interferon-stimulated ubiquitin-like protein, is not essential for STAT1 signaling and responses against vesicular stomatitis and lymphocytic choriomeningitis virus. Molecular and Cell Biology 2005, 25(August (15)):6338-6345.
49. Harty R.N., Pitha P.M., Okumura A. Antiviral activity of innate immune protein ISG15. Journal of Innate Immunity 2009, 1(5):397-404.
50. Shi H.X., Yang K., Liu X., Liu X.Y., Wei B., Shan Y.F., et al. Positive regulation of interferon regulatory factor 3 activation by Herc5 via ISG15 modification. Molecular and Cell Biology 2010, 30(May (10)):2424-2436.
51. Jeon Y.J., Choi J.S., Lee J.Y., Yu K.R., Kim S.M., Ka S.H., et al. ISG15 modification of filamin B negatively regulates the type I interferon-induced JNK signalling pathway. EMBO Reports 2009, 10(April (4)):374-380.
52. Kim M.J., Hwang S.Y., Imaizumi T., Yoo J.Y. Negative feedback regulation of RIG-I-mediated antiviral signaling by interferon-induced ISG15 conjugation. Journal of Virology 2008, 82(February (3)):1474-1483.
53. Giannakopoulos N.V., Luo J.K., Papov V., Zou W., Lenschow D.J., Jacobs B.S., et al. Proteomic identification of proteins conjugated to ISG15 in mouse and human cells. Biochemical and Biophysical Research Communications 2005, 336(October (2)):496-506.
54. Zhao C., Denison C., Huibregtse J.M., Gygi S., Krug R.M. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proceedings of the National Academy of Sciences U S A 2005, 102(July (29)):10200-10205.
55. Wong J.J., Pung Y.F., Sze N.S., Chin K.C. HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. Proceedings of the National Academy of Sciences U S A 2006, 103(July (28)):10735-10740.
56. Takeuchi T., Iwahara S., Saeki Y., Sasajima H., Yokosawa H. Link between the ubiquitin conjugation system and the ISG15 conjugation system: ISG15 conjugation to the UbcH6 ubiquitin E2 enzyme. The Journal of Biological Chemistry 2005, 138(December (6)):711-719.
57. Takeuchi T., Yokosawa H. ISG15 modification of Ubc13 suppresses its ubiquitin-conjugating activity. Biochemical and Biophysical Research Communications 2005, 336(October (1)):9-13.
58. Zou W., Papov V., Malakhova O., Kim K.I., Dao C., Li J., et al. ISG15 modification of ubiquitin E2 Ubc13 disrupts its ability to form thioester bond with ubiquitin. Biochemical and Biophysical Research Communications 2005, 336(October (1)):61-68.
59. Malakhova O.A., Zhang D.E. ISG15 inhibits Nedd4 ubiquitin E3 activity and enhances the innate antiviral response. The Journal of Biological Chemistry 2008, 283(April (14)):8783-8787.
60. D'Cunha J., Knight E., Haas A.L., Truitt R.L., Borden E.C. Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proceedings of the National Academy of Sciences U S A 1996, 93(January (1)):211-215.
61. Owhashi M., Taoka Y., Ishii K., Nakazawa S., Uemura H., Kambara H. Identification of a ubiquitin family protein as a novel neutrophil chemotactic factor. Biochemical and Biophysical Research Communications 2003, 309(September (3)):533-539.
62. Borden E.C., Lindner D., Dreicer R., Hussein M., Peereboom D. Second-generation interferons for cancer: clinical targets. Seminars in Cancer Biology 2000, 10(April (2)):125-144.
63. Kiladjian J.J., Mesa R.A., Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood 2011, 117(May (18)):4706-4715.
64. Rizza P., Moretti F., Belardelli F. Recent advances on the immunomodulatory effects of IFN-alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity 2010, 43(April (3)):204-209.
65. Paquette R.L., Hsu N., Said J., Mohammed M., Rao N.P., Shih G., et al. Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo. Leukemia 2002, 16(August (8)):1484-1489.
66. Chen X., Regn S., Raffegerst S., Kolb H.J., Roskrow M. Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemia. British Journal of Haematology 2000, 111(November (2)):596-607.
67. Biron C.A. Interferons alpha and beta as immune regulators-a new look. Immunity 2001, 14(June (6)):661-664.
68. Indraccolo S. Interferon-alpha as angiogenesis inhibitor: learning from tumor models. Autoimmunity 2010, 43(April (3)):244-247.
69. Chawla-Sarkar M., Lindner D.J., Liu Y.F., Williams B.R., Sen G.C., Silverman R.H., et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003, 8(June (3)):237-249.
70. Borden E.C. Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma. Cytokine and Growth Factor Reviews 2007, 18(October-December (5-6)):491-501.
71. Cavalli L.R., Riggins R.B., Wang A., Clarke R., Haddad B.R. Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer. Breast Cancer Research and Treatment 2010, 121(May (1)):227-231.
72. Katsoulidis E., Sassano A., Majchrzak-Kita B., Carayol N., Yoon P., Jordan A., et al. Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells. The Journal of Biological Chemistry 2008, 283(April (16)):10793-10803.
73. Einav U., Tabach Y., Getz G., Yitzhaky A., Ozbek U., Amariglio N., et al. Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer. Oncogene 2005, 24(September (42)):6367-6375.
74. Hornakova T., Chiaretti S., Lemaire M.M., Foa R., Ben Abdelali R., Asnafi V., et al. ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon. Blood 2010, 115(April (16)):3287-3295.
75. Weichselbaum R.R., Ishwaran H., Yoon T., Nuyten D.S., Baker S.W., Khodarev N., et al. An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proceedings of the National Academy of Sciences U S A 2008, 105(November (47)):18490-18495.
76. Gongora C., Candeil L., Vezzio N., Copois V., Denis V., Breil C., et al. Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38. Cancer Biology and Therapy 2008, 7(June (6)):822-832.
77. Khodarev N.N., Beckett M., Labay E., Darga T., Roizman B., Weichselbaum R.R. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proceedings of the National Academy of Sciences U S A 2004, 101(February (6)):1714-1719.
78. Khodarev N.N., Minn A.J., Efimova E.V., Darga T.E., Labay E., Beckett M., et al. Signal transducer and activator of transcription 1 regulates both cytotoxic and prosurvival functions in tumor cells. Cancer Research 2007, 67(October (19)):9214-9220.
79. Tsai Y.C., Pestka S., Wang L.H., Runnels L.W., Wan S., Lyu Y.L., et al. Interferon-beta signaling contributes to Ras transformation. PLoS ONE 2011, 6(8):e24291.
80. Ascierto M.L., Kmieciak M., Idowu M.O., Manjili R., Zhao Y., Grimes M., et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Research and Treatment 2012, 131(February (3)):871-880.
81. Chen J.J., Knudsen S., Mazin W., Dahlgaard J., Zhang B. A 71-gene signature of TRAIL sensitivity in cancer cells. Molecular Cancer Therapeutics 2012, 11(January (1)):34-44.
82. Andersen J.B., Aaboe M., Borden E.C., Goloubeva O.G., Hassel B.A., Orntoft T.F. Stage-associated overexpression of the ubiquitin-like protein ISG15, in bladder cancer. British Journal of Cancer 2006, 94(May (10)):1465-1471.
83. Bektas N., Noetzel E., Veeck J., Press M.F., Kristiansen G., Naami A., et al. The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Research 2008, 10(4):R58.
84. Satake H., Tamura K., Furihata M., Anchi T., Sakoda H., Kawada C., et al. The ubiquitin-like molecule interferon-stimulated gene 15 is overexpressed in human prostate cancer. Oncology Reports 2010, 23(January (1)):11-16.
85. Kiessling A., Hogrefe C., Erb S., Bobach C., Fuessel S., Wessjohann L., et al. Expression, regulation and function of the ISGylation system in prostate cancer. Oncogene 2009, 28(July (28)):2606-2620.
86. Ye H., Yu T., Temam S., Ziober B.L., Wang J., Schwartz J.L., et al. Transcriptomic dissection of tongue squamous cell carcinoma. BMC Genomics 2008, 9:69.
87. Chi L.M., Lee C.W., Chang K.P., Hao S.P., Lee H.M., Liang Y., et al. Enhanced interferon signaling pathway in oral cancer revealed by quantitative proteome analysis of microdissected specimens using 16O/18O labeling and integrated two-dimensional LC-ESI-MALDI tandem MS. Molecular and Cellular Proteomics 2009, 8(July (7)):1453-1474.
88. Sgarlato G.D., Eastman C.L., Sussman H.H. Panel of genes transcriptionally up-regulated in squamous cell carcinoma of the cervix identified by representational difference analysis, confirmed by macroarray, and validated by real-time quantitative reverse transcription-PCR. Clinical Chemistry 2005, 51(January (1)):27-34.
89. Andersen J.B., Hassel B.A. The interferon regulated ubiquitin-like protein, ISG15, in tumorigenesis: friend or foe?. Cytokine and Growth Factor Reviews 2006, 17(December (6)):411-421.
90. Duarte C.W., Willey C.D., Zhi D., Cui X., Harris J.J., Vaughan L.K., et al. Expression signature of IFN/STAT1 signaling genes predicts poor survival outcome in glioblastoma multiforme in a subtype-specific manner. PLoS ONE 2012, 7(1):e29653.
91. D'Cunha J., Ramanujam S., Wagner R.J., Witt P.L., Knight E., Borden E.C. In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. The Journal of Immunology 1996, 157(November (9)):4100-4108.
92. Wu C.C., Hsu C.W., Chen C.D., Yu C.J., Chang K.P., Tai D.I., et al. Candidate serological biomarkers for cancer identified from the secretomes of 23 cancer cell lines and the human protein atlas. Molecular and Cellular Proteomics 2010, 9(June (6)):1100-1117.
93. Padovan E., Terracciano L., Certa U., Jacobs B., Reschner A., Bolli M., et al. Interferon stimulated gene 15 constitutively produced by melanoma cells induces e-cadherin expression on human dendritic cells. Cancer Research 2002, 62(June (12)):3453-3458.
94. Kok K., van den Berg A., Veldhuis P.M., van der Veen A.Y., Franke M., Schoenmakers E.F., et al. A homozygous deletion in a small cell lung cancer cell line involving a 3p21 region with a marked instability in yeast artificial chromosomes. Cancer Research 1994, 54(August (15)):4183-4187.
95. McLaughlin P.M., Helfrich W., Kok K., Mulder M., Hu S.W., Brinker M.G., et al. The ubiquitin-activating enzyme E1-like protein in lung cancer cell lines. International Journal of Cancer 2000, 85(March (6)):871-876.
96. Kok K., Van den Berg A., Veldhuis P.M., Franke M., Terpstra P., Buys C.H. The genomic structure of the human UBE1L gene. Gene Expression 1995, 4(3):163-175.
97. Yin X., Cong X., Yan M., Zhang D.E. Deficiency of a potential 3p21.3 tumor suppressor gene UBE1L (UBA7) does not accelerate lung cancer development in K-rasLA2 mice. Lung Cancer 2009, 63(February (2)):194-200.
98. Pitha-Rowe I., Petty W.J., Feng Q., Koza-Taylor P.H., Dimattia D.A., Pinder L., et al. Microarray analyses uncover UBE1L as a candidate target gene for lung cancer chemoprevention. Cancer Research 2004, 64(November (21)):8109-8115.
99. Feng Q., Sekula D., Guo Y., Liu X., Black C.C., Galimberti F., et al. UBE1L causes lung cancer growth suppression by targeting cyclin D1. Molecular Cancer Therapeutics 2008, 7(December (12)):3780-3788.
100. Kitareewan S., Pitha-Rowe I., Sekula D., Lowrey C.H., Nemeth M.J., Golub T.R., et al. UBE1L is a retinoid target that triggers PML/RARalpha degradation and apoptosis in acute promyelocytic leukemia. Proceedings of the National Academy of Sciences U S A 2002, 99(March (6)):3806-3811.
101. Indraccolo S., Pfeffer U., Minuzzo S., Esposito G., Roni V., Mandruzzato S., et al. Identification of genes selectively regulated by IFNs in endothelial cells. The Journal of Immunology 2007, 178(January (2)):1122-1135.
102. Sanda C., Weitzel P., Tsukahara T., Schaley J., Edenberg H.J., Stephens M.A., et al. Differential gene induction by type I and type II interferons and their combination. The Journal of Interferon and Cytokine Research 2006, 26(July (7)):462-472.
103. Yu K., Ganesan K., Tan L.K., Laban M., Wu J., Zhao X.D., et al. A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers. PLos Genetics 2008, 4(7):e1000129.
104. Murat A., Migliavacca E., Gorlia T., Lambiv W.L., Shay T., Hamou M.F., et al. Stem cell-related " self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. Journal of Clinical Oncology 2008, 26(June (18)):3015-3024.
105. Bild A.H., Yao G., Chang J.T., Wang Q., Potti A., Chasse D., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006, 439(January (7074)):353-357.
106. Badea L., Herlea V., Dima S.O., Dumitrascu T., Popescu I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepato-Gastroenterology 2008, 55(November-December (88)):2016-2027.
107. Pei H., Li L., Fridley B.L., Jenkins G.D., Kalari K.R., Lingle W., et al. FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cells 2009, 16(September (3)):259-266.
108. Jorissen R.N., Lipton L., Gibbs P., Chapman M., Desai J., Jones I.T., et al. DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers. Clinical Cancer Research 2008, 14(December (24)):8061-8069.
109. Talantov D., Mazumder A., Yu J.X., Briggs T., Jiang Y., Backus J., et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clinical Cancer Research 2005, 11(October (20)):7234-7242.
110. Riker A.I., Enkemann S.A., Fodstad O., Liu S., Ren S., Morris C., et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Medical Genomics 2008, 1:13.
111. Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cells 2006, 10(December (6)):515-527.
112. Hoeflich K.P., O'Brien C., Boyd Z., Cavet G., Guerrero S., Jung K., et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clinical Cancer Research 2009, 15(July (14)):4649-4664.
113. Wagner K.W., Punnoose E.A., Januario T., Lawrence D.A., Pitti R.M., Lancaster K., et al. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nature Medicine 2007, 13(September (9)):1070-1077.
114. Altman D. Practical statistics for medical research 1991, Chapman & Hall.